German Cancer Aid

The Mark Foundation for Cancer Research Appoints Two New Members to Board of Directors

Retrieved on: 
Wednesday, May 10, 2023

NEW YORK, May 10, 2023 /PRNewswire/ -- The Mark Foundation for Cancer Research announced today the appointment of two new members to its Board of Directors. Nicola Mendelsohn CBE, Head of Global Business at Meta, and Otmar Wiestler, MD, President of the Helmholtz Association, Germany's largest scientific organization, were elected at The Mark Foundation's April board meeting. Their terms are effective immediately. Both new board members are well-positioned and uniquely qualified to support the Foundation's mission of accelerating research that will transform the prevention, diagnosis, and treatment of cancer.

Key Points: 
  • Nicola Mendelsohn CBE, Head of Global Business Group at Meta, and Otmar Wiestler, President of Helmholtz Association, join board of global leader in cancer research funding
    NEW YORK, May 10, 2023 /PRNewswire/ -- The Mark Foundation for Cancer Research announced today the appointment of two new members to its Board of Directors.
  • Both new board members are well-positioned and uniquely qualified to support the Foundation's mission of accelerating research that will transform the prevention, diagnosis, and treatment of cancer.
  • "We are honored to welcome these distinguished members to The Mark Foundation Board of Directors," said Ray DuBois, MD, PhD, Executive Chairman.
  • "The Mark Foundation is committed to accelerating cancer research on a global scale; since 2017 they have funded outstanding grantees in 13 countries," said Otmar Wiestler.

Global Natural Killer (NK) Cell Therapeutics Market Trends, Competitive Landscape & Clinical Trials Insights Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 30, 2023

The "Global Natural Killer (NK) Cell Therapeutics Market Trends, Companies & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Natural Killer (NK) Cell Therapeutics Market Trends, Companies & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • To carry out its cytotoxic activity, NK cells contain granzymes and perforins which cause the target cell to lyse.
  • For a NK cell therapy, the process of generation of NK cells is the same as that for T cell therapy.
  • Partnerships & Funding for Natural Killer Cell Therapies: > 10 Recent Deals
    Global Natural Killer Cell Therapies Clinical Trials Insight: > 200 Therapies
    Global Natural Killer Cell Therapies Clinical Trials by Company, Indication & Phase
    Proprietary Technologies by Company Insight: > 10 Technologies

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

Retrieved on: 
Tuesday, March 21, 2023

NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors.

Key Points: 
  • NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors.
  • Dr. Hoos currently serves as the Chief Executive Officer of Scorpion Therapeutics and brings a wealth of business, entrepreneurial and biopharmaceutical research and development expertise to the role.
  • “Dr.
  • I am looking forward to working with the executive team and fellow Board members to help NextPoint realize its promise to deliver the next IO breakthrough,” said Dr. Hoos.

Viessmann Group in 2022, Its 105th Anniversary Year: Driven by a Lot of Positive Energy, the Family Company Achieved Record Revenues of EUR 4 Billion and Growth of +19 Percent

Retrieved on: 
Wednesday, February 1, 2023

In its 105th anniversary year, the family company increased its total revenue to EUR 4 billion.

Key Points: 
  • In its 105th anniversary year, the family company increased its total revenue to EUR 4 billion.
  • This corresponds to an increase of +19 percent compared to total revenue of EUR 3.4 billion in the previous year.
  • Max Viessmann, CEO of the Viessmann Group: "In our 105th anniversary year, we have taken additional responsibility by facing the crises and challenges.
  • In May 2022, the family company announced its plans to invest EUR 1 billion in the expansion of green climate solutions.

EQS-News: Viessmann Group in 2022, its 105th anniversary year: Driven by a lot of positive energy, the family company achieved record revenues of EUR 4 billion and growth of +19 percent

Retrieved on: 
Thursday, February 2, 2023

In its 105th anniversary year, the family company increased its total revenue to EUR 4 billion.

Key Points: 
  • In its 105th anniversary year, the family company increased its total revenue to EUR 4 billion.
  • This corresponds to an increase of +19 percent compared to total revenue of EUR 3.4 billion in the previous year.
  • Max Viessmann, CEO of the Viessmann Group: "In our 105th anniversary year, we have taken additional responsibility by facing the crises and challenges.
  • In May 2022, the family company announced its plans to invest EUR 1 billion in the expansion of green climate solutions.

EQS-News: HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

Retrieved on: 
Sunday, November 27, 2022

Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.

Key Points: 
  • Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.
  • We are thrilled to welcome Andreas Busch to our team.
  • Dr. Andreas Busch added: There is an enormous lack of organs for transplantation including of livers despite their unique inherent regenerative capabilities.
  • Dr. Andreas Busch has an extensive track record in facilitating innovation both in the pharmaceutical industry as well as in academic research.

BGV appoints Elena Ritsou as Venture Partner and Andree Blaukat as Senior Advisor

Retrieved on: 
Tuesday, November 8, 2022

Amsterdam, The Netherlands 8 November 2022 BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, today announces the appointments of Dr. Elena Ritsou as Venture Partner and Dr. Andree Blaukat as Senior Advisor, further expanding its team, network and expertise in company creation and building.

Key Points: 
  • Amsterdam, The Netherlands 8 November 2022 BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, today announces the appointments of Dr. Elena Ritsou as Venture Partner and Dr. Andree Blaukat as Senior Advisor, further expanding its team, network and expertise in company creation and building.
  • Dr. Andree Blaukat, newly appointed Senior Advisor at BGV added: BGV has one of the leading most experienced early-stage life sciences venture teams in Europe.
  • Dr. Elena Ritsou, newly appointed Venture Partner at BGV commented: Europe has been particularly strong in life sciences innovation and the industry is expanding and maturing fast.
  • Edward Van Wezel, Managing Partner at BGV noted: Both Elena and Andree are experienced leaders in the life sciences industry.

Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

Retrieved on: 
Tuesday, October 4, 2022

VANCOUVER, Wash. and NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological data to design better therapeutics, faster, today announced the appointment of Andreas Busch, PhD, as Chief Innovation Officer, where he will be responsible for leading R&D, technical operations, and driving both Absci’s internal and partner programs. As a former pharma R&D executive, Dr. Busch brings substantial R&D expertise to Absci’s leadership team as a world-renowned leader in drug development that has led discovery efforts for some of the globe’s top pharma companies including Sanofi, Bayer, and Shire. His leadership has resulted in over 10 commercial drugs starting from bench to FDA approval with several more in late stage clinical development.

Key Points: 
  • Absci has addressed this data problem through its breakthrough wet lab technology that can interrogate millions-to-billions of protein-protein interactions in a given week.
  • Prior to joining Absci, Dr. Busch served as Chief Scientific Officer and Chief Innovation Officer, Head of the Innovation Center at Cyclerion Therapeutics, Inc., an innovator in CNS biotherapeutics.
  • Before Cyclerion, Dr. Busch served as Executive Vice President, Head of Research & Development and Chief Scientific Officer at Shire prior to their acquisition by Takeda.
  • For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio , LinkedIn: @absci , and subscribe to our Absci YouTube channel .

Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.

Retrieved on: 
Monday, June 27, 2022

DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors.

Key Points: 
  • DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors.
  • Diane is an innovator and strategist with extensive experience in the biopharmaceutical industry, and we are delighted to welcome her to the Humacyte board, said Kathleen Sebelius, Chair of Humacytes board of directors.
  • Her expertise in guiding companies with innovative products to the market will be invaluable as Humacyte moves toward commercialization of the Human Acellular VesselTM (HAV).
  • Dr. Seimetz brings more than 22 years of international drug development, partnering and managerial experience in the biopharmaceutical industry to the Humacyte board.

Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer

Retrieved on: 
Monday, June 13, 2022

Asher Biotherapeutics, Inc. (Asher Bio) , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Andrea Pirzkall, M.D., as its first Chief Medical Officer.

Key Points: 
  • Asher Biotherapeutics, Inc. (Asher Bio) , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Andrea Pirzkall, M.D., as its first Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220613005157/en/
    Asher Bio CMO Andrea Pirzkall MD (Photo: Business Wire)
    We are delighted to welcome Andrea to the Asher Bio team at this pivotal time as we transition to a clinical-stage company.
  • Andrea is an ideal fit to our team as we continue to advance our pipeline, said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.
  • For more information, please visit www.asherbio.com and follow Asher Bio on Twitter @AsherBio and on LinkedIn .